Delving into the Latest Updates on Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute) with Synapse

Overview

Basic Info

Drug Type

Universal CAR-T

Synonyms

4SCAR7U

Target

CD7

Mechanism

CD7 modulators(T-cell antigen CD7 modulators), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Acute Myeloid LeukemiaCD7 positive Hematologic NeoplasmsCD7 Positive Neoplasms+ [3]

Inactive Indication-

Originator Organization

Shenzhen Geno-Immune Medical Institute

Active Organization

Shenzhen Geno-Immune Medical Institute

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.

Start Date31 Oct 2023

Sponsor / Collaborator

Shenzhen Geno-Immune Medical Institute

NCT04033302 / Unknown statusPhase 1/2IIT

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells. The study also aims to learn more about the function of CD7 CAR T cells and their persistence in patients of hematological malignancies.

Start Date01 Sep 2019

Sponsor / Collaborator

Shenzhen Geno-Immune Medical Institute

100 Clinical Results associated with Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute)

Login to view more data

100 Translational Medicine associated with Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute)

Login to view more data

100 Patents (Medical) associated with Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute)

Login to view more data

100 Deals associated with Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 1	CN	Shenzhen Geno-Immune Medical Institute	31 Oct 2023
CD7 positive Hematologic Neoplasms	Phase 1	CN	Shenzhen Geno-Immune Medical Institute	31 Oct 2023
CD7 Positive Neoplasms	Phase 1	CN	Shenzhen Geno-Immune Medical Institute	31 Oct 2023
NK-cell lymphoma	Phase 1	CN	Shenzhen Geno-Immune Medical Institute	31 Oct 2023
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	Phase 1	CN	Shenzhen Geno-Immune Medical Institute	31 Oct 2023
T-cell Acute Lymphoblastic Leukemia/Lymphoma	Phase 1	CN	Shenzhen Geno-Immune Medical Institute	31 Oct 2023